Overview

PS-341 in Treating Women With Metastatic Breast Cancer

Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating women who have metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborator:
National Cancer Institute (NCI)
Treatments:
Bortezomib
Proteasome Inhibitors